Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Point72 Asset Management reports 8% passive stake in Allena Pharmaceuticals » 17:41
12/10/20
12/10
17:41
12/10/20
17:41
ALNA

Allena Pharmaceuticals

$1.30 /

+0.015 (+1.17%)

Point72 Asset Management…

Point72 Asset Management disclosed a 8.0% stake in Allena Pharmaceuticals, which represents 4M shares. The filing does not allow for activism.

ShowHide Related Items >><<
ALNA Allena Pharmaceuticals
$1.30 /

+0.015 (+1.17%)

ALNA Allena Pharmaceuticals
$1.30 /

+0.015 (+1.17%)

10/01/20 B. Riley Securities
Allena Pharmaceuticals price target raised to $5 from $4 at B. Riley Securities
06/01/20 H.C. Wainwright
Allena Pharmaceuticals initiated with a Buy at H.C. Wainwright
03/18/20 Roth Capital
Allena Pharmaceuticals price target lowered to $11 from $31 at Roth Capital
02/12/20 Roth Capital
Streamlining makes Allena URIROX-2 path clear, says Roth Capital
ALNA Allena Pharmaceuticals
$1.30 /

+0.015 (+1.17%)

  • 02
    Dec
Syndicate
Allena Pharmaceuticals 10.4M share Spot Secondary priced at $1.25 » 06:33
12/02/20
12/02
06:33
12/02/20
06:33
ALNA

Allena Pharmaceuticals

$1.33 /

-0.02 (-1.49%)

The deal size was…

The deal size was increased to 10.4M shares of common stock from 8M shares of common stock. H.C. Wainwright acted as sole book running manager for the offering.

ShowHide Related Items >><<
ALNA Allena Pharmaceuticals
$1.33 /

-0.02 (-1.49%)

ALNA Allena Pharmaceuticals
$1.33 /

-0.02 (-1.49%)

10/01/20 B. Riley Securities
Allena Pharmaceuticals price target raised to $5 from $4 at B. Riley Securities
06/01/20 H.C. Wainwright
Allena Pharmaceuticals initiated with a Buy at H.C. Wainwright
03/18/20 Roth Capital
Allena Pharmaceuticals price target lowered to $11 from $31 at Roth Capital
02/12/20 Roth Capital
Streamlining makes Allena URIROX-2 path clear, says Roth Capital
ALNA Allena Pharmaceuticals
$1.33 /

-0.02 (-1.49%)

  • 02
    Dec
Syndicate
Allena Pharmaceuticals announces $10M bought deal offering » 17:02
12/01/20
12/01
17:02
12/01/20
17:02
ALNA

Allena Pharmaceuticals

$1.33 /

-0.02 (-1.49%)

Allena Pharmaceuticals…

Allena Pharmaceuticals announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., under which the underwriter has agreed to purchase on a firm commitment basis 8M shares of common stock of the company, at a price to the public of $1.25 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about December 4, subject to satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the sole book-running manager for the offering. The company intends to use the net proceeds from this offering for working capital and other general corporate purposes.

ShowHide Related Items >><<
ALNA Allena Pharmaceuticals
$1.33 /

-0.02 (-1.49%)

ALNA Allena Pharmaceuticals
$1.33 /

-0.02 (-1.49%)

10/01/20 B. Riley Securities
Allena Pharmaceuticals price target raised to $5 from $4 at B. Riley Securities
06/01/20 H.C. Wainwright
Allena Pharmaceuticals initiated with a Buy at H.C. Wainwright
03/18/20 Roth Capital
Allena Pharmaceuticals price target lowered to $11 from $31 at Roth Capital
02/12/20 Roth Capital
Streamlining makes Allena URIROX-2 path clear, says Roth Capital
ALNA Allena Pharmaceuticals
$1.33 /

-0.02 (-1.49%)

Hot Stocks
Allena Pharmaceuticals appoints David Clark as CMO » 08:37
12/01/20
12/01
08:37
12/01/20
08:37
ALNA

Allena Pharmaceuticals

$1.35 /

-0.115 (-7.88%)

, ALDX

Aldeyra

$7.03 /

+0.13 (+1.88%)

Allena Pharmaceuticals…

Allena Pharmaceuticals (ALNA) announced the appointment of David Clark, M.D., M.R.C.P, as CMO, effective immediately. Dr. Clark succeeds Annamaria Kausz, M.D., who will transition to supporting the company in an advisory capacity. Most recently, he served as CMO of Aldeyra Therapeutics (ALDX) from 2016 to 2020, where he led the clinical development and regulatory functions for a portfolio of Phase 3 and Phase 2 programs across a range of immune-mediated ocular and systemic diseases

ShowHide Related Items >><<
ALNA Allena Pharmaceuticals
$1.35 /

-0.115 (-7.88%)

ALDX Aldeyra
$7.03 /

+0.13 (+1.88%)

ALNA Allena Pharmaceuticals
$1.35 /

-0.115 (-7.88%)

10/01/20 B. Riley Securities
Allena Pharmaceuticals price target raised to $5 from $4 at B. Riley Securities
06/01/20 H.C. Wainwright
Allena Pharmaceuticals initiated with a Buy at H.C. Wainwright
03/18/20 Roth Capital
Allena Pharmaceuticals price target lowered to $11 from $31 at Roth Capital
02/12/20 Roth Capital
Streamlining makes Allena URIROX-2 path clear, says Roth Capital
ALDX Aldeyra
$7.03 /

+0.13 (+1.88%)

11/06/20 Alliance Global Partners
Aldeyra 'loading bases' for reproxalap 'blowout,' says Alliance Global Partners
10/30/20
Fly Intel: Top five analyst initiations
10/30/20 Jefferies
Aldeyra initiated with a Buy at Jefferies
10/16/20 BTIG
Aldeyra initiated with a Buy at BTIG
ALNA Allena Pharmaceuticals
$1.35 /

-0.115 (-7.88%)

ALDX Aldeyra
$7.03 /

+0.13 (+1.88%)

Hot Stocks
Allena Pharmaceuticals announces initial data from Phase 1 trial of ALLN-346 » 08:10
11/30/20
11/30
08:10
11/30/20
08:10
ALNA

Allena Pharmaceuticals

$1.46 /

+0.075 (+5.42%)

Allena Pharmaceuticals…

Allena Pharmaceuticals announced clinical data from its Phase 1 trial of ALLN-346 in healthy volunteers. ALLN-346 is an investigational, orally administered, novel urate-degrading enzyme that has been designed for activity and stability in the gastrointestinal tract, and is intended for the treatment of hyperuricemia in patients with gout and chronic kidney disease. The double-blind, placebo-controlled, single-ascending dose study enrolled 24 healthy volunteers. Groups of eight study participants were randomized 3:1 to ALLN-346 or matching placebo in three sequential cohorts dosed orally with three, six, or 12 capsules in one day. Each capsule of ALLN-346 contained a target dose of 90 mg of enzyme, equivalent to 2,250 units. ALLN-346 was well-tolerated with no clinically significant safety signals and no dose-limiting toxicities observed in any cohort up to the highest administered dose. In addition, assay of serum samples by ELISA immunoassay demonstrated that ALLN-346 was not absorbed systemically, supporting that its mechanism of action appears to be restricted to the GI tract. Subject to feedback from the U.S. Food and Drug Administration, Allena expects to initiate a Phase 1b multiple-ascending dose trial in healthy volunteers and a Phase 2 proof-of-concept trial in patients with hyperuricemia and CKD in the first half of 2021, with initial data from both studies expected in the second half of 2021.

ShowHide Related Items >><<
ALNA Allena Pharmaceuticals
$1.46 /

+0.075 (+5.42%)

ALNA Allena Pharmaceuticals
$1.46 /

+0.075 (+5.42%)

10/01/20 B. Riley Securities
Allena Pharmaceuticals price target raised to $5 from $4 at B. Riley Securities
06/01/20 H.C. Wainwright
Allena Pharmaceuticals initiated with a Buy at H.C. Wainwright
03/18/20 Roth Capital
Allena Pharmaceuticals price target lowered to $11 from $31 at Roth Capital
02/12/20 Roth Capital
Streamlining makes Allena URIROX-2 path clear, says Roth Capital
ALNA Allena Pharmaceuticals
$1.46 /

+0.075 (+5.42%)

Syndicate
Allena Pharmaceuticals files to sell 6.1M shares of common stock for holders  08:09
11/27/20
11/27
08:09
11/27/20
08:09
ALNA

Allena Pharmaceuticals

$1.39 /

+0.045 (+3.36%)

 
ShowHide Related Items >><<
ALNA Allena Pharmaceuticals
$1.39 /

+0.045 (+3.36%)

ALNA Allena Pharmaceuticals
$1.39 /

+0.045 (+3.36%)

10/01/20 B. Riley Securities
Allena Pharmaceuticals price target raised to $5 from $4 at B. Riley Securities
06/01/20 H.C. Wainwright
Allena Pharmaceuticals initiated with a Buy at H.C. Wainwright
03/18/20 Roth Capital
Allena Pharmaceuticals price target lowered to $11 from $31 at Roth Capital
02/12/20 Roth Capital
Streamlining makes Allena URIROX-2 path clear, says Roth Capital
ALNA Allena Pharmaceuticals
$1.39 /

+0.045 (+3.36%)

Conference/Events
Jefferies to hold a virtual conference » 04:55
11/19/20
11/19
04:55
11/19/20
04:55
MRNA

Moderna

$88.90 /

-4.225 (-4.54%)

, IMGN

ImmunoGen

$5.75 /

-0.035 (-0.61%)

, ESPR

Esperion

$29.18 /

-0.95 (-3.15%)

, CRL

Charles River

$234.11 /

-2.205 (-0.93%)

, AXGN

AxoGen

$15.16 /

-0.05 (-0.33%)

, INMD

InMode

$42.75 /

+0.16 (+0.38%)

, PRTA

Prothena

$12.10 /

-0.24 (-1.94%)

, SYNH

Syneos Health

$63.21 /

-0.24 (-0.38%)

, RDNT

RadNet

$18.19 /

-0.75 (-3.96%)

, OPNT

Opiant Pharmaceuticals

$7.95 /

+0.2 (+2.58%)

, FGEN

FibroGen

$41.56 /

-2.58 (-5.85%)

, MGLN

Magellan Health

$82.25 /

-2.47 (-2.92%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, CARA

Cara Therapeutics

$15.66 /

-0.53 (-3.27%)

, IVA

Inventiva

$14.00 /

+ (+0.00%)

, ITOS

iTeos Therapeutics

$25.09 /

+1.14 (+4.76%)

, CLBS

Caladrius

$1.44 /

-0.055 (-3.68%)

, ALNA

Allena Pharmaceuticals

$1.37 /

-0.07 (-4.86%)

, SEEL

Seelos Therapeutics

$0.78 /

-0.0296 (-3.65%)

, SMMNY

Siemens Healthineers

$0.00 /

+ (+0.00%)

, CNCE

Concert Pharmaceuticals

$10.82 /

-0.23 (-2.08%)

Virtual Healthcare…

Virtual Healthcare Conference will be held on November 17-19.

ShowHide Related Items >><<
SYNH Syneos Health
$63.21 /

-0.24 (-0.38%)

SMMNY Siemens Healthineers
$0.00 /

+ (+0.00%)

SEEL Seelos Therapeutics
$0.78 /

-0.0296 (-3.65%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RDNT RadNet
$18.19 /

-0.75 (-3.96%)

PRTA Prothena
$12.10 /

-0.24 (-1.94%)

OPNT Opiant Pharmaceuticals
$7.95 /

+0.2 (+2.58%)

MRNA Moderna
$88.90 /

-4.225 (-4.54%)

MGLN Magellan Health
$82.25 /

-2.47 (-2.92%)

IVA Inventiva
$14.00 /

+ (+0.00%)

ITOS iTeos Therapeutics
$25.09 /

+1.14 (+4.76%)

INMD InMode
$42.75 /

+0.16 (+0.38%)

IMGN ImmunoGen
$5.75 /

-0.035 (-0.61%)

FGEN FibroGen
$41.56 /

-2.58 (-5.85%)

ESPR Esperion
$29.18 /

-0.95 (-3.15%)

CRL Charles River
$234.11 /

-2.205 (-0.93%)

CNCE Concert Pharmaceuticals
$10.82 /

-0.23 (-2.08%)

CLBS Caladrius
$1.44 /

-0.055 (-3.68%)

CARA Cara Therapeutics
$15.66 /

-0.53 (-3.27%)

AXGN AxoGen
$15.16 /

-0.05 (-0.33%)

ALNA Allena Pharmaceuticals
$1.37 /

-0.07 (-4.86%)

MRNA Moderna
$88.90 /

-4.225 (-4.54%)

11/17/20 Benchmark
Inovio on 'top-10 vaccine contenders list,' says Benchmark
11/17/20 Maxim
Co-Diagnostics price target lowered to $20 from $30 at Maxim
11/17/20 Roth Capital
Inovio downgraded to Sell at Roth Capital on increased competition
11/17/20 Redburn
Moderna initiated with a Sell at Redburn
IMGN ImmunoGen
$5.75 /

-0.035 (-0.61%)

10/26/20 H.C. Wainwright
ImmunoGen assumed with a Buy at H.C. Wainwright
10/19/20 Piper Sandler
Greater China partnership 'very favorable' for ImmunoGen, says Piper Sandler
10/05/20 Piper Sandler
Piper says r/r BPDCN revenue opportunity for ImmunoGen's 632 'an open question'
10/02/20 Guggenheim
ImmunoGen upgraded to Buy from Neutral at Guggenheim
ESPR Esperion
$29.18 /

-0.95 (-3.15%)

11/10/20 Credit Suisse
Esperion upgraded to Outperform from Neutral at Credit Suisse
09/29/20 JPMorgan
Esperion resumed with an Underweight at JPMorgan
08/10/20 Credit Suisse
Esperion downgraded to Neutral from Outperform at Credit Suisse
05/07/20 Citi
Esperion price target raised to $56 from $46 at Citi
CRL Charles River
$234.11 /

-2.205 (-0.93%)

11/03/20 Truist
Charles River price target raised to $256 from $237 at Truist
10/30/20 Deutsche Bank
Charles River price target raised to $250 from $235 at Deutsche Bank
09/14/20 Argus
Charles River price target raised to $235 from $190 at Argus
09/10/20
Fly Intel: Top five analyst upgrades
AXGN AxoGen
$15.16 /

-0.05 (-0.33%)

10/22/20 Guggenheim
AxoGen initiated with a Buy at Guggenheim
06/16/20 Cantor Fitzgerald
AxoGen assumed with an Overweight at Cantor Fitzgerald
06/15/20 Cantor Fitzgerald
AxoGen assumed with an Overweight at Cantor Fitzgerald
05/07/20 Canaccord
AxoGen downgraded to Hold at Canaccord
INMD InMode
$42.75 /

+0.16 (+0.38%)

10/21/20 Canaccord
InMode price target raised to $51 from $42 at Canaccord
10/13/20 Baird
InMode price target raised to $55 from $43 at Baird
02/19/20 Barclays
InMode price target raised to $48 from $45 at Barclays
01/28/20 Baird
InMode price target raised to $55 from $45 at Baird
PRTA Prothena
$12.10 /

-0.24 (-1.94%)

10/21/20 Cantor Fitzgerald
Prothena price target raised to $24 from $20 at Cantor Fitzgerald
07/09/20 Oppenheimer
Prothena upgraded to Outperform at Oppenheimer
07/09/20 Oppenheimer
Prothena upgraded to Outperform from Perform at Oppenheimer
11/19/19 Evercore ISI
Prothena upgraded to Outperform on valuation at Evercore ISI
SYNH Syneos Health
$63.21 /

-0.24 (-0.38%)

10/06/20 Mizuho
Syneos Health upgraded to Buy on attractive entry point at Mizuho
10/06/20 Mizuho
Syneos Health upgraded to Buy from Neutral at Mizuho
10/01/20 Goldman Sachs
Syneos Health upgraded to Buy from Neutral at Goldman Sachs
08/12/20 Truist
Syneos Health price target raised to $80 from $74 at Truist
RDNT RadNet
$18.19 /

-0.75 (-3.96%)

09/03/20 Clarus
Akumin can re-rate as Nasdaq listing raises U.S. awareness, says Clarus
OPNT Opiant Pharmaceuticals
$7.95 /

+0.2 (+2.58%)

FGEN FibroGen
$41.56 /

-2.58 (-5.85%)

10/26/20 Raymond James
FibroGen initiated with an Underperform at Raymond James
10/26/20 Raymond James
FibroGen initiated with an Underperform at Raymond James
10/23/20 Stifel
FibroGen safety data mitigates concerns of roxadustat black box, says Stifel
09/04/20 Stifel
FibroGen's roxadustat can be 'dominant leader' as competitor fades, says Stifel
MGLN Magellan Health
$82.25 /

-2.47 (-2.92%)

11/13/20
Fly Intel: Top five analyst upgrades
11/13/20 Stephens
Magellan Health upgraded to Overweight from Equal Weight at Stephens
RHHBY Roche
$0.00 /

+ (+0.00%)

11/11/20 Truist
Opthea initiated with a Buy at Truist
10/16/20 UBS
Roche price target lowered to CHF 370 from CHF 390 at UBS
10/06/20 Goldman Sachs
Goldman reiterates $34 target on Kiniksa after 'impressive' data
09/29/20 Berenberg
Roche initiated with a Hold at Berenberg
CARA Cara Therapeutics
$15.66 /

-0.53 (-3.27%)

10/20/20 H.C. Wainwright
Cara deal with 'perfect partner' Vifor boosts confidence at H.C. Wainwright
04/22/20 Cantor Fitzgerald
Cara Therapeutics price target raised to $34 from $26 at Cantor Fitzgerald
04/21/20 H.C. Wainwright
Cara Therapeutics price target raised to $33 from $30 at H.C. Wainwright
01/10/20 Stifel
Cara Therapeutics named a BioPharma top pick for 2020 at Stifel
IVA Inventiva
$14.00 /

+ (+0.00%)

10/13/20 Roth Capital
Roth backs Buy on Inventiva after Lanifibranor given breakthrough designation
08/17/20 H.C. Wainwright
Inventiva price target raised to $38 from EUR 12 at H.C. Wainwright
08/05/20
Fly Intel: Top five analyst initiations
08/05/20 Roth Capital
Inventiva initiated with a Buy at Roth Capital
ITOS iTeos Therapeutics
$25.09 /

+1.14 (+4.76%)

10/07/20 Baird
iTeos Therapeutics initiated with an Outperform at Baird
09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
09/01/20 Piper Sandler
iTeos Therapeutics heading for 'catalyst rich stretch', says Piper Sandler
08/18/20 SVB Leerink
SVB Leerink bullish on iTeos Therapeutics, initiates with an Outperform
CLBS Caladrius
$1.44 /

-0.055 (-3.68%)

05/22/20 Brookline
Caladrius initiated with a Buy at Brookline
05/18/20 Dawson James
Caladrius downgraded to Neutral from Buy at Dawson James
ALNA Allena Pharmaceuticals
$1.37 /

-0.07 (-4.86%)

10/01/20 B. Riley Securities
Allena Pharmaceuticals price target raised to $5 from $4 at B. Riley Securities
06/01/20 H.C. Wainwright
Allena Pharmaceuticals initiated with a Buy at H.C. Wainwright
03/18/20 Roth Capital
Allena Pharmaceuticals price target lowered to $11 from $31 at Roth Capital
02/12/20 Roth Capital
Streamlining makes Allena URIROX-2 path clear, says Roth Capital
SEEL Seelos Therapeutics
$0.78 /

-0.0296 (-3.65%)

09/09/20 Roth Capital
Seelos Therapeutics shares 'substantially undervalued,' says Roth Capital
06/23/20 Roth Capital
Seelos Therapeutics price target raised to $12 from $8 Roth Capital
SMMNY Siemens Healthineers
$0.00 /

+ (+0.00%)

11/10/20 Credit Suisse
Siemens Healthineers price target raised to EUR 44 from EUR 43 at Credit Suisse
10/28/20 Barrington
Varian Medical downgraded to Underperform from Outperform at Barrington
10/26/20 RBC Capital
Siemens Healthineers price target lowered to EUR 42 from EUR 45 at RBC Capital
10/06/20 Deutsche Bank
Siemens Healthineers price target lowered to EUR 39 at Deutsche Bank
CNCE Concert Pharmaceuticals
$10.82 /

-0.23 (-2.08%)

11/04/20 JMP Securities
Concert Pharmaceuticals resumed with an Outperform at JMP Securities
03/30/20
Fly Intel: Top five analyst initiations
03/30/20 Jefferies
Concert Pharmaceuticals initiated with a Buy at Jefferies
02/27/20 Stifel
Concert Pharmaceuticals price target raised to $11 from $8 at Stifel
SYNH Syneos Health
$63.21 /

-0.24 (-0.38%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RDNT RadNet
$18.19 /

-0.75 (-3.96%)

PRTA Prothena
$12.10 /

-0.24 (-1.94%)

OPNT Opiant Pharmaceuticals
$7.95 /

+0.2 (+2.58%)

MRNA Moderna
$88.90 /

-4.225 (-4.54%)

MGLN Magellan Health
$82.25 /

-2.47 (-2.92%)

ITOS iTeos Therapeutics
$25.09 /

+1.14 (+4.76%)

INMD InMode
$42.75 /

+0.16 (+0.38%)

IMGN ImmunoGen
$5.75 /

-0.035 (-0.61%)

FGEN FibroGen
$41.56 /

-2.58 (-5.85%)

ESPR Esperion
$29.18 /

-0.95 (-3.15%)

CRL Charles River
$234.11 /

-2.205 (-0.93%)

CNCE Concert Pharmaceuticals
$10.82 /

-0.23 (-2.08%)

CLBS Caladrius
$1.44 /

-0.055 (-3.68%)

CARA Cara Therapeutics
$15.66 /

-0.53 (-3.27%)

AXGN AxoGen
$15.16 /

-0.05 (-0.33%)

ALNA Allena Pharmaceuticals
$1.37 /

-0.07 (-4.86%)

  • 16
    Sep
  • 24
    Jul
  • 10
    Jul
  • 19
    May
  • 12
    Mar
  • 11
    Feb
  • 12
    Feb
  • 28
    Jan
  • 21
    Jan
RHHBY Roche
$0.00 /

+ (+0.00%)

MRNA Moderna
$88.90 /

-4.225 (-4.54%)

SYNH Syneos Health
$63.21 /

-0.24 (-0.38%)

SMMNY Siemens Healthineers
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

MRNA Moderna
$88.90 /

-4.225 (-4.54%)

IVA Inventiva
$14.00 /

+ (+0.00%)

ITOS iTeos Therapeutics
$25.09 /

+1.14 (+4.76%)

IMGN ImmunoGen
$5.75 /

-0.035 (-0.61%)

FGEN FibroGen
$41.56 /

-2.58 (-5.85%)

ESPR Esperion
$29.18 /

-0.95 (-3.15%)

CARA Cara Therapeutics
$15.66 /

-0.53 (-3.27%)

AXGN AxoGen
$15.16 /

-0.05 (-0.33%)

MRNA Moderna
$88.90 /

-4.225 (-4.54%)

FGEN FibroGen
$41.56 /

-2.58 (-5.85%)

ESPR Esperion
$29.18 /

-0.95 (-3.15%)

Conference/Events
Jefferies to hold a virtual conference » 04:55
11/18/20
11/18
04:55
11/18/20
04:55
MRNA

Moderna

$93.12 /

-4.88 (-4.98%)

, IMGN

ImmunoGen

$5.78 /

+0.03 (+0.52%)

, ESPR

Esperion

$30.13 /

+0.02 (+0.07%)

, CRL

Charles River

$236.30 /

-1.56 (-0.66%)

, AXGN

AxoGen

$15.29 /

+0.18 (+1.19%)

, INMD

InMode

$42.61 /

+0.8 (+1.91%)

, PRTA

Prothena

$12.34 /

-0.03 (-0.24%)

, SYNH

Syneos Health

$63.45 /

-0.37 (-0.58%)

, RDNT

RadNet

$18.94 /

-0.05 (-0.26%)

, OPNT

Opiant Pharmaceuticals

$7.78 /

-0.02 (-0.26%)

, FGEN

FibroGen

$44.14 /

+1.12 (+2.60%)

, MGLN

Magellan Health

$84.72 /

-0.64 (-0.75%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, CARA

Cara Therapeutics

$16.19 /

+0.5 (+3.19%)

, IVA

Inventiva

$14.00 /

+0.175 (+1.27%)

, ITOS

iTeos Therapeutics

$23.95 /

-0.08 (-0.33%)

, CLBS

Caladrius

$1.50 /

-0.005 (-0.33%)

, ALNA

Allena Pharmaceuticals

$1.43 /

-0.15 (-9.49%)

, SEEL

Seelos Therapeutics

$0.81 /

-0.0119 (-1.45%)

, SMMNY

Siemens Healthineers

$0.00 /

+ (+0.00%)

, CNCE

Concert Pharmaceuticals

$11.04 /

+0.03 (+0.27%)

Virtual Healthcare…

Virtual Healthcare Conference will be held on November 17-19.

ShowHide Related Items >><<
SYNH Syneos Health
$63.45 /

-0.37 (-0.58%)

SMMNY Siemens Healthineers
$0.00 /

+ (+0.00%)

SEEL Seelos Therapeutics
$0.81 /

-0.0119 (-1.45%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RDNT RadNet
$18.94 /

-0.05 (-0.26%)

PRTA Prothena
$12.34 /

-0.03 (-0.24%)

OPNT Opiant Pharmaceuticals
$7.78 /

-0.02 (-0.26%)

MRNA Moderna
$93.12 /

-4.88 (-4.98%)

MGLN Magellan Health
$84.72 /

-0.64 (-0.75%)

IVA Inventiva
$14.00 /

+0.175 (+1.27%)

ITOS iTeos Therapeutics
$23.95 /

-0.08 (-0.33%)

INMD InMode
$42.61 /

+0.8 (+1.91%)

IMGN ImmunoGen
$5.78 /

+0.03 (+0.52%)

FGEN FibroGen
$44.14 /

+1.12 (+2.60%)

ESPR Esperion
$30.13 /

+0.02 (+0.07%)

CRL Charles River
$236.30 /

-1.56 (-0.66%)

CNCE Concert Pharmaceuticals
$11.04 /

+0.03 (+0.27%)

CLBS Caladrius
$1.50 /

-0.005 (-0.33%)

CARA Cara Therapeutics
$16.19 /

+0.5 (+3.19%)

AXGN AxoGen
$15.29 /

+0.18 (+1.19%)

ALNA Allena Pharmaceuticals
$1.43 /

-0.15 (-9.49%)

MRNA Moderna
$93.12 /

-4.88 (-4.98%)

11/17/20 Benchmark
Inovio on 'top-10 vaccine contenders list,' says Benchmark
11/17/20 Maxim
Co-Diagnostics price target lowered to $20 from $30 at Maxim
11/17/20 Roth Capital
Inovio downgraded to Sell at Roth Capital on increased competition
11/17/20 Redburn
Moderna initiated with a Sell at Redburn
IMGN ImmunoGen
$5.78 /

+0.03 (+0.52%)

10/26/20 H.C. Wainwright
ImmunoGen assumed with a Buy at H.C. Wainwright
10/19/20 Piper Sandler
Greater China partnership 'very favorable' for ImmunoGen, says Piper Sandler
10/05/20 Piper Sandler
Piper says r/r BPDCN revenue opportunity for ImmunoGen's 632 'an open question'
10/02/20 Guggenheim
ImmunoGen upgraded to Buy from Neutral at Guggenheim
ESPR Esperion
$30.13 /

+0.02 (+0.07%)

11/10/20 Credit Suisse
Esperion upgraded to Outperform from Neutral at Credit Suisse
09/29/20 JPMorgan
Esperion resumed with an Underweight at JPMorgan
08/10/20 Credit Suisse
Esperion downgraded to Neutral from Outperform at Credit Suisse
05/07/20 Citi
Esperion price target raised to $56 from $46 at Citi
CRL Charles River
$236.30 /

-1.56 (-0.66%)

11/03/20 Truist
Charles River price target raised to $256 from $237 at Truist
10/30/20 Deutsche Bank
Charles River price target raised to $250 from $235 at Deutsche Bank
09/14/20 Argus
Charles River price target raised to $235 from $190 at Argus
09/10/20
Fly Intel: Top five analyst upgrades
AXGN AxoGen
$15.29 /

+0.18 (+1.19%)

10/22/20 Guggenheim
AxoGen initiated with a Buy at Guggenheim
06/16/20 Cantor Fitzgerald
AxoGen assumed with an Overweight at Cantor Fitzgerald
06/15/20 Cantor Fitzgerald
AxoGen assumed with an Overweight at Cantor Fitzgerald
05/07/20 Canaccord
AxoGen downgraded to Hold at Canaccord
INMD InMode
$42.61 /

+0.8 (+1.91%)

10/21/20 Canaccord
InMode price target raised to $51 from $42 at Canaccord
10/13/20 Baird
InMode price target raised to $55 from $43 at Baird
02/19/20 Barclays
InMode price target raised to $48 from $45 at Barclays
01/28/20 Baird
InMode price target raised to $55 from $45 at Baird
PRTA Prothena
$12.34 /

-0.03 (-0.24%)

10/21/20 Cantor Fitzgerald
Prothena price target raised to $24 from $20 at Cantor Fitzgerald
07/09/20 Oppenheimer
Prothena upgraded to Outperform at Oppenheimer
07/09/20 Oppenheimer
Prothena upgraded to Outperform from Perform at Oppenheimer
11/19/19 Evercore ISI
Prothena upgraded to Outperform on valuation at Evercore ISI
SYNH Syneos Health
$63.45 /

-0.37 (-0.58%)

10/06/20 Mizuho
Syneos Health upgraded to Buy on attractive entry point at Mizuho
10/06/20 Mizuho
Syneos Health upgraded to Buy from Neutral at Mizuho
10/01/20 Goldman Sachs
Syneos Health upgraded to Buy from Neutral at Goldman Sachs
08/12/20 Truist
Syneos Health price target raised to $80 from $74 at Truist
RDNT RadNet
$18.94 /

-0.05 (-0.26%)

09/03/20 Clarus
Akumin can re-rate as Nasdaq listing raises U.S. awareness, says Clarus
OPNT Opiant Pharmaceuticals
$7.78 /

-0.02 (-0.26%)

FGEN FibroGen
$44.14 /

+1.12 (+2.60%)

10/26/20 Raymond James
FibroGen initiated with an Underperform at Raymond James
10/26/20 Raymond James
FibroGen initiated with an Underperform at Raymond James
10/23/20 Stifel
FibroGen safety data mitigates concerns of roxadustat black box, says Stifel
09/04/20 Stifel
FibroGen's roxadustat can be 'dominant leader' as competitor fades, says Stifel
MGLN Magellan Health
$84.72 /

-0.64 (-0.75%)

11/13/20
Fly Intel: Top five analyst upgrades
11/13/20 Stephens
Magellan Health upgraded to Overweight from Equal Weight at Stephens
RHHBY Roche
$0.00 /

+ (+0.00%)

11/11/20 Truist
Opthea initiated with a Buy at Truist
10/16/20 UBS
Roche price target lowered to CHF 370 from CHF 390 at UBS
10/06/20 Goldman Sachs
Goldman reiterates $34 target on Kiniksa after 'impressive' data
09/29/20 Berenberg
Roche initiated with a Hold at Berenberg
CARA Cara Therapeutics
$16.19 /

+0.5 (+3.19%)

10/20/20 H.C. Wainwright
Cara deal with 'perfect partner' Vifor boosts confidence at H.C. Wainwright
04/22/20 Cantor Fitzgerald
Cara Therapeutics price target raised to $34 from $26 at Cantor Fitzgerald
04/21/20 H.C. Wainwright
Cara Therapeutics price target raised to $33 from $30 at H.C. Wainwright
01/10/20 Stifel
Cara Therapeutics named a BioPharma top pick for 2020 at Stifel
IVA Inventiva
$14.00 /

+0.175 (+1.27%)

10/13/20 Roth Capital
Roth backs Buy on Inventiva after Lanifibranor given breakthrough designation
08/17/20 H.C. Wainwright
Inventiva price target raised to $38 from EUR 12 at H.C. Wainwright
08/05/20
Fly Intel: Top five analyst initiations
08/05/20 Roth Capital
Inventiva initiated with a Buy at Roth Capital
ITOS iTeos Therapeutics
$23.95 /

-0.08 (-0.33%)

10/07/20 Baird
iTeos Therapeutics initiated with an Outperform at Baird
09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
09/01/20 Piper Sandler
iTeos Therapeutics heading for 'catalyst rich stretch', says Piper Sandler
08/18/20 SVB Leerink
SVB Leerink bullish on iTeos Therapeutics, initiates with an Outperform
CLBS Caladrius
$1.50 /

-0.005 (-0.33%)

05/22/20 Brookline
Caladrius initiated with a Buy at Brookline
05/18/20 Dawson James
Caladrius downgraded to Neutral from Buy at Dawson James
ALNA Allena Pharmaceuticals
$1.43 /

-0.15 (-9.49%)

10/01/20 B. Riley Securities
Allena Pharmaceuticals price target raised to $5 from $4 at B. Riley Securities
06/01/20 H.C. Wainwright
Allena Pharmaceuticals initiated with a Buy at H.C. Wainwright
03/18/20 Roth Capital
Allena Pharmaceuticals price target lowered to $11 from $31 at Roth Capital
02/12/20 Roth Capital
Streamlining makes Allena URIROX-2 path clear, says Roth Capital
SEEL Seelos Therapeutics
$0.81 /

-0.0119 (-1.45%)

09/09/20 Roth Capital
Seelos Therapeutics shares 'substantially undervalued,' says Roth Capital
06/23/20 Roth Capital
Seelos Therapeutics price target raised to $12 from $8 Roth Capital
11/18/19 H.C. Wainwright
Seelos Therapeutics price target lowered to $2 from $4 at H.C. Wainwright
SMMNY Siemens Healthineers
$0.00 /

+ (+0.00%)

11/10/20 Credit Suisse
Siemens Healthineers price target raised to EUR 44 from EUR 43 at Credit Suisse
10/28/20 Barrington
Varian Medical downgraded to Underperform from Outperform at Barrington
10/26/20 RBC Capital
Siemens Healthineers price target lowered to EUR 42 from EUR 45 at RBC Capital
10/06/20 Deutsche Bank
Siemens Healthineers price target lowered to EUR 39 at Deutsche Bank
CNCE Concert Pharmaceuticals
$11.04 /

+0.03 (+0.27%)

11/04/20 JMP Securities
Concert Pharmaceuticals resumed with an Outperform at JMP Securities
03/30/20
Fly Intel: Top five analyst initiations
03/30/20 Jefferies
Concert Pharmaceuticals initiated with a Buy at Jefferies
02/27/20 Stifel
Concert Pharmaceuticals price target raised to $11 from $8 at Stifel
SYNH Syneos Health
$63.45 /

-0.37 (-0.58%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RDNT RadNet
$18.94 /

-0.05 (-0.26%)

PRTA Prothena
$12.34 /

-0.03 (-0.24%)

OPNT Opiant Pharmaceuticals
$7.78 /

-0.02 (-0.26%)

MRNA Moderna
$93.12 /

-4.88 (-4.98%)

MGLN Magellan Health
$84.72 /

-0.64 (-0.75%)

ITOS iTeos Therapeutics
$23.95 /

-0.08 (-0.33%)

INMD InMode
$42.61 /

+0.8 (+1.91%)

IMGN ImmunoGen
$5.78 /

+0.03 (+0.52%)

FGEN FibroGen
$44.14 /

+1.12 (+2.60%)

ESPR Esperion
$30.13 /

+0.02 (+0.07%)

CRL Charles River
$236.30 /

-1.56 (-0.66%)

CNCE Concert Pharmaceuticals
$11.04 /

+0.03 (+0.27%)

CLBS Caladrius
$1.50 /

-0.005 (-0.33%)

CARA Cara Therapeutics
$16.19 /

+0.5 (+3.19%)

AXGN AxoGen
$15.29 /

+0.18 (+1.19%)

ALNA Allena Pharmaceuticals
$1.43 /

-0.15 (-9.49%)

  • 16
    Sep
  • 24
    Jul
  • 10
    Jul
  • 19
    May
  • 12
    Mar
  • 11
    Feb
  • 12
    Feb
  • 28
    Jan
  • 21
    Jan
RHHBY Roche
$0.00 /

+ (+0.00%)

MRNA Moderna
$93.12 /

-4.88 (-4.98%)

SYNH Syneos Health
$63.45 /

-0.37 (-0.58%)

SMMNY Siemens Healthineers
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

MRNA Moderna
$93.12 /

-4.88 (-4.98%)

IVA Inventiva
$14.00 /

+0.175 (+1.27%)

ITOS iTeos Therapeutics
$23.95 /

-0.08 (-0.33%)

IMGN ImmunoGen
$5.78 /

+0.03 (+0.52%)

FGEN FibroGen
$44.14 /

+1.12 (+2.60%)

ESPR Esperion
$30.13 /

+0.02 (+0.07%)

CARA Cara Therapeutics
$16.19 /

+0.5 (+3.19%)

AXGN AxoGen
$15.29 /

+0.18 (+1.19%)

MRNA Moderna
$93.12 /

-4.88 (-4.98%)

FGEN FibroGen
$44.14 /

+1.12 (+2.60%)

ESPR Esperion
$30.13 /

+0.02 (+0.07%)

Conference/Events
Jefferies to hold a virtual conference » 08:54
11/17/20
11/17
08:54
11/17/20
08:54
MRNA

Moderna

$97.95 /

+8.65 (+9.69%)

, IMGN

ImmunoGen

$5.75 /

-0.1 (-1.71%)

, ESPR

Esperion

$30.11 /

+1.45 (+5.06%)

, CRL

Charles River

$237.94 /

-0.75 (-0.31%)

, AXGN

AxoGen

$15.09 /

+0.445 (+3.04%)

, INMD

InMode

$41.88 /

-0.01 (-0.02%)

, PRTA

Prothena

$12.37 /

+0.07 (+0.57%)

, SYNH

Syneos Health

$63.82 /

+0.48 (+0.76%)

, RDNT

RadNet

$18.99 /

+0.43 (+2.32%)

, OPNT

Opiant Pharmaceuticals

$7.83 /

+0.045 (+0.58%)

, FGEN

FibroGen

$43.03 /

+0.79 (+1.87%)

, MGLN

Magellan Health

$85.23 /

+0.11 (+0.13%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, CARA

Cara Therapeutics

$15.69 /

+0.28 (+1.82%)

, IVA

Inventiva

$14.00 /

-0.005 (-0.04%)

, ITOS

iTeos Therapeutics

$24.03 /

+0.36 (+1.52%)

, CLBS

Caladrius

$1.50 /

-0.01 (-0.66%)

, ALNA

Allena Pharmaceuticals

$1.58 /

+0.07 (+4.64%)

, SEEL

Seelos Therapeutics

$0.82 /

-0.0299 (-3.52%)

, SMMNY

Siemens Healthineers

$0.00 /

+ (+0.00%)

, CNCE

Concert Pharmaceuticals

$11.01 /

-0.05 (-0.45%)

Virtual Healthcare…

Virtual Healthcare Conference will be held on November 17-19.

ShowHide Related Items >><<
SYNH Syneos Health
$63.82 /

+0.48 (+0.76%)

SMMNY Siemens Healthineers
$0.00 /

+ (+0.00%)

SEEL Seelos Therapeutics
$0.82 /

-0.0299 (-3.52%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RDNT RadNet
$18.99 /

+0.43 (+2.32%)

PRTA Prothena
$12.37 /

+0.07 (+0.57%)

OPNT Opiant Pharmaceuticals
$7.83 /

+0.045 (+0.58%)

MRNA Moderna
$97.95 /

+8.65 (+9.69%)

MGLN Magellan Health
$85.23 /

+0.11 (+0.13%)

IVA Inventiva
$14.00 /

-0.005 (-0.04%)

ITOS iTeos Therapeutics
$24.03 /

+0.36 (+1.52%)

INMD InMode
$41.88 /

-0.01 (-0.02%)

IMGN ImmunoGen
$5.75 /

-0.1 (-1.71%)

FGEN FibroGen
$43.03 /

+0.79 (+1.87%)

ESPR Esperion
$30.11 /

+1.45 (+5.06%)

CRL Charles River
$237.94 /

-0.75 (-0.31%)

CNCE Concert Pharmaceuticals
$11.01 /

-0.05 (-0.45%)

CLBS Caladrius
$1.50 /

-0.01 (-0.66%)

CARA Cara Therapeutics
$15.69 /

+0.28 (+1.82%)

AXGN AxoGen
$15.09 /

+0.445 (+3.04%)

ALNA Allena Pharmaceuticals
$1.58 /

+0.07 (+4.64%)

MRNA Moderna
$97.95 /

+8.65 (+9.69%)

11/17/20 Maxim
Co-Diagnostics price target lowered to $20 from $30 at Maxim
11/17/20 Roth Capital
Inovio downgraded to Sell at Roth Capital on increased competition
11/17/20 Redburn
Moderna initiated with a Sell at Redburn
11/17/20 BMO Capital
Moderna downgraded to Market Perform from Outperform at BMO Capital
IMGN ImmunoGen
$5.75 /

-0.1 (-1.71%)

10/26/20 H.C. Wainwright
ImmunoGen assumed with a Buy at H.C. Wainwright
10/19/20 Piper Sandler
Greater China partnership 'very favorable' for ImmunoGen, says Piper Sandler
10/05/20 Piper Sandler
Piper says r/r BPDCN revenue opportunity for ImmunoGen's 632 'an open question'
10/02/20 Guggenheim
ImmunoGen upgraded to Buy from Neutral at Guggenheim
ESPR Esperion
$30.11 /

+1.45 (+5.06%)

11/10/20 Credit Suisse
Esperion upgraded to Outperform from Neutral at Credit Suisse
09/29/20 JPMorgan
Esperion resumed with an Underweight at JPMorgan
08/10/20 Credit Suisse
Esperion downgraded to Neutral from Outperform at Credit Suisse
05/07/20 Citi
Esperion price target raised to $56 from $46 at Citi
CRL Charles River
$237.94 /

-0.75 (-0.31%)

11/03/20 Truist
Charles River price target raised to $256 from $237 at Truist
10/30/20 Deutsche Bank
Charles River price target raised to $250 from $235 at Deutsche Bank
09/14/20 Argus
Charles River price target raised to $235 from $190 at Argus
09/10/20
Fly Intel: Top five analyst upgrades
AXGN AxoGen
$15.09 /

+0.445 (+3.04%)

10/22/20 Guggenheim
AxoGen initiated with a Buy at Guggenheim
06/16/20 Cantor Fitzgerald
AxoGen assumed with an Overweight at Cantor Fitzgerald
06/15/20 Cantor Fitzgerald
AxoGen assumed with an Overweight at Cantor Fitzgerald
05/07/20 Canaccord
AxoGen downgraded to Hold at Canaccord
INMD InMode
$41.88 /

-0.01 (-0.02%)

10/21/20 Canaccord
InMode price target raised to $51 from $42 at Canaccord
10/13/20 Baird
InMode price target raised to $55 from $43 at Baird
02/19/20 Barclays
InMode price target raised to $48 from $45 at Barclays
01/28/20 Baird
InMode price target raised to $55 from $45 at Baird
PRTA Prothena
$12.37 /

+0.07 (+0.57%)

10/21/20 Cantor Fitzgerald
Prothena price target raised to $24 from $20 at Cantor Fitzgerald
07/09/20 Oppenheimer
Prothena upgraded to Outperform at Oppenheimer
07/09/20 Oppenheimer
Prothena upgraded to Outperform from Perform at Oppenheimer
11/19/19 Evercore ISI
Prothena upgraded to Outperform on valuation at Evercore ISI
SYNH Syneos Health
$63.82 /

+0.48 (+0.76%)

10/06/20 Mizuho
Syneos Health upgraded to Buy on attractive entry point at Mizuho
10/06/20 Mizuho
Syneos Health upgraded to Buy from Neutral at Mizuho
10/01/20 Goldman Sachs
Syneos Health upgraded to Buy from Neutral at Goldman Sachs
08/12/20 Truist
Syneos Health price target raised to $80 from $74 at Truist
RDNT RadNet
$18.99 /

+0.43 (+2.32%)

09/03/20 Clarus
Akumin can re-rate as Nasdaq listing raises U.S. awareness, says Clarus
OPNT Opiant Pharmaceuticals
$7.83 /

+0.045 (+0.58%)

FGEN FibroGen
$43.03 /

+0.79 (+1.87%)

10/26/20 Raymond James
FibroGen initiated with an Underperform at Raymond James
10/26/20 Raymond James
FibroGen initiated with an Underperform at Raymond James
10/23/20 Stifel
FibroGen safety data mitigates concerns of roxadustat black box, says Stifel
09/04/20 Stifel
FibroGen's roxadustat can be 'dominant leader' as competitor fades, says Stifel
MGLN Magellan Health
$85.23 /

+0.11 (+0.13%)

11/13/20
Fly Intel: Top five analyst upgrades
11/13/20 Stephens
Magellan Health upgraded to Overweight from Equal Weight at Stephens
RHHBY Roche
$0.00 /

+ (+0.00%)

11/11/20 Truist
Opthea initiated with a Buy at Truist
10/16/20 UBS
Roche price target lowered to CHF 370 from CHF 390 at UBS
10/06/20 Goldman Sachs
Goldman reiterates $34 target on Kiniksa after 'impressive' data
09/29/20 Berenberg
Roche initiated with a Hold at Berenberg
CARA Cara Therapeutics
$15.69 /

+0.28 (+1.82%)

10/20/20 H.C. Wainwright
Cara deal with 'perfect partner' Vifor boosts confidence at H.C. Wainwright
04/22/20 Cantor Fitzgerald
Cara Therapeutics price target raised to $34 from $26 at Cantor Fitzgerald
04/21/20 H.C. Wainwright
Cara Therapeutics price target raised to $33 from $30 at H.C. Wainwright
01/10/20 Stifel
Cara Therapeutics named a BioPharma top pick for 2020 at Stifel
IVA Inventiva
$14.00 /

-0.005 (-0.04%)

10/13/20 Roth Capital
Roth backs Buy on Inventiva after Lanifibranor given breakthrough designation
08/17/20 H.C. Wainwright
Inventiva price target raised to $38 from EUR 12 at H.C. Wainwright
08/05/20
Fly Intel: Top five analyst initiations
08/05/20 Roth Capital
Inventiva initiated with a Buy at Roth Capital
ITOS iTeos Therapeutics
$24.03 /

+0.36 (+1.52%)

10/07/20 Baird
iTeos Therapeutics initiated with an Outperform at Baird
09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
09/01/20 Piper Sandler
iTeos Therapeutics heading for 'catalyst rich stretch', says Piper Sandler
08/18/20 SVB Leerink
SVB Leerink bullish on iTeos Therapeutics, initiates with an Outperform
CLBS Caladrius
$1.50 /

-0.01 (-0.66%)

05/22/20 Brookline
Caladrius initiated with a Buy at Brookline
05/18/20 Dawson James
Caladrius downgraded to Neutral from Buy at Dawson James
ALNA Allena Pharmaceuticals
$1.58 /

+0.07 (+4.64%)

10/01/20 B. Riley Securities
Allena Pharmaceuticals price target raised to $5 from $4 at B. Riley Securities
06/01/20 H.C. Wainwright
Allena Pharmaceuticals initiated with a Buy at H.C. Wainwright
03/18/20 Roth Capital
Allena Pharmaceuticals price target lowered to $11 from $31 at Roth Capital
02/12/20 Roth Capital
Streamlining makes Allena URIROX-2 path clear, says Roth Capital
SEEL Seelos Therapeutics
$0.82 /

-0.0299 (-3.52%)

09/09/20 Roth Capital
Seelos Therapeutics shares 'substantially undervalued,' says Roth Capital
06/23/20 Roth Capital
Seelos Therapeutics price target raised to $12 from $8 Roth Capital
11/18/19 H.C. Wainwright
Seelos Therapeutics price target lowered to $2 from $4 at H.C. Wainwright
SMMNY Siemens Healthineers
$0.00 /

+ (+0.00%)

11/10/20 Credit Suisse
Siemens Healthineers price target raised to EUR 44 from EUR 43 at Credit Suisse
10/28/20 Barrington
Varian Medical downgraded to Underperform from Outperform at Barrington
10/26/20 RBC Capital
Siemens Healthineers price target lowered to EUR 42 from EUR 45 at RBC Capital
10/06/20 Deutsche Bank
Siemens Healthineers price target lowered to EUR 39 at Deutsche Bank
CNCE Concert Pharmaceuticals
$11.01 /

-0.05 (-0.45%)

11/04/20 JMP Securities
Concert Pharmaceuticals resumed with an Outperform at JMP Securities
03/30/20
Fly Intel: Top five analyst initiations
03/30/20 Jefferies
Concert Pharmaceuticals initiated with a Buy at Jefferies
02/27/20 Stifel
Concert Pharmaceuticals price target raised to $11 from $8 at Stifel
SYNH Syneos Health
$63.82 /

+0.48 (+0.76%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RDNT RadNet
$18.99 /

+0.43 (+2.32%)

PRTA Prothena
$12.37 /

+0.07 (+0.57%)

OPNT Opiant Pharmaceuticals
$7.83 /

+0.045 (+0.58%)

MRNA Moderna
$97.95 /

+8.65 (+9.69%)

MGLN Magellan Health
$85.23 /

+0.11 (+0.13%)

ITOS iTeos Therapeutics
$24.03 /

+0.36 (+1.52%)

INMD InMode
$41.88 /

-0.01 (-0.02%)

IMGN ImmunoGen
$5.75 /

-0.1 (-1.71%)

FGEN FibroGen
$43.03 /

+0.79 (+1.87%)

ESPR Esperion
$30.11 /

+1.45 (+5.06%)

CRL Charles River
$237.94 /

-0.75 (-0.31%)

CNCE Concert Pharmaceuticals
$11.01 /

-0.05 (-0.45%)

CLBS Caladrius
$1.50 /

-0.01 (-0.66%)

CARA Cara Therapeutics
$15.69 /

+0.28 (+1.82%)

AXGN AxoGen
$15.09 /

+0.445 (+3.04%)

ALNA Allena Pharmaceuticals
$1.58 /

+0.07 (+4.64%)

  • 16
    Sep
  • 24
    Jul
  • 10
    Jul
  • 19
    May
  • 12
    Mar
  • 11
    Feb
  • 12
    Feb
  • 28
    Jan
  • 21
    Jan
RHHBY Roche
$0.00 /

+ (+0.00%)

MRNA Moderna
$97.95 /

+8.65 (+9.69%)

SYNH Syneos Health
$63.82 /

+0.48 (+0.76%)

SMMNY Siemens Healthineers
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

MRNA Moderna
$97.95 /

+8.65 (+9.69%)

IVA Inventiva
$14.00 /

-0.005 (-0.04%)

ITOS iTeos Therapeutics
$24.03 /

+0.36 (+1.52%)

IMGN ImmunoGen
$5.75 /

-0.1 (-1.71%)

FGEN FibroGen
$43.03 /

+0.79 (+1.87%)

ESPR Esperion
$30.11 /

+1.45 (+5.06%)

CARA Cara Therapeutics
$15.69 /

+0.28 (+1.82%)

AXGN AxoGen
$15.09 /

+0.445 (+3.04%)

MRNA Moderna
$97.95 /

+8.65 (+9.69%)

FGEN FibroGen
$43.03 /

+0.79 (+1.87%)

ESPR Esperion
$30.11 /

+1.45 (+5.06%)

Conference/Events
H.C. Wainwright to hold a virtual conference » 09:29
11/12/20
11/12
09:29
11/12/20
09:29
BWAY

Brainsway

$6.02 /

+0.12 (+2.03%)

, ENTX

Entera Bio

$1.10 /

+ (+0.00%)

, NMTR

9 Meters Biopharma

$0.71 /

+0.0053 (+0.76%)

, ZDGE

Zedge, Inc.

$3.06 /

-0.04 (-1.29%)

, ALNA

Allena Pharmaceuticals

$1.51 /

+ (+0.00%)

6th Annual Israel Virtual…

6th Annual Israel Virtual Conference will be held on November 12. Webcast Link

ShowHide Related Items >><<
ZDGE Zedge, Inc.
$3.06 /

-0.04 (-1.29%)

NMTR 9 Meters Biopharma
$0.71 /

+0.0053 (+0.76%)

ENTX Entera Bio
$1.10 /

+ (+0.00%)

BWAY Brainsway
$6.02 /

+0.12 (+2.03%)

ALNA Allena Pharmaceuticals
$1.51 /

+ (+0.00%)

BWAY Brainsway
$6.02 /

+0.12 (+2.03%)

03/24/20 Raymond James
Brainsway price target lowered to $9 from $13 at Raymond James
03/24/20 Cantor Fitzgerald
Brainsway price target lowered to $13 from $17 at Cantor Fitzgerald
ENTX Entera Bio
$1.10 /

+ (+0.00%)

NMTR 9 Meters Biopharma
$0.71 /

+0.0053 (+0.76%)

10/30/20
Fly Intel: Top five analyst initiations
10/30/20 Maxim
9 Meters Biopharma initiated with a Buy at Maxim
09/23/20 William Blair
9 Meters Biopharma initiated with an Outperform at William Blair
08/17/20 Brookline
9 Meters Biopharma initiated with a Buy at Brookline
ZDGE Zedge, Inc.
$3.06 /

-0.04 (-1.29%)

ALNA Allena Pharmaceuticals
$1.51 /

+ (+0.00%)

10/01/20 B. Riley Securities
Allena Pharmaceuticals price target raised to $5 from $4 at B. Riley Securities
06/01/20 H.C. Wainwright
Allena Pharmaceuticals initiated with a Buy at H.C. Wainwright
03/18/20 Roth Capital
Allena Pharmaceuticals price target lowered to $11 from $31 at Roth Capital
02/12/20 Roth Capital
Streamlining makes Allena URIROX-2 path clear, says Roth Capital
BWAY Brainsway
$6.02 /

+0.12 (+2.03%)

ALNA Allena Pharmaceuticals
$1.51 /

+ (+0.00%)

ENTX Entera Bio
$1.10 /

+ (+0.00%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.